On Jun. 10, 2013, Sanofi Pasteur announced the U.S. Food and Drug Administration (FDA) had approved the supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent vaccine.

Fluzone Quadrivalent vaccine was the newest addition to the Fluzone family of influenza vaccines. Fluzone Quadrivalent vaccine is licensed for use in children six months of age and older, adolescents, and adults.